Targeting NSCLC with Precision: Evaluation of the Emerging Role of Antibody-Drug Conjugates : Episode 9
Opinion
Video
Optimizing Therapy Selection in EGFR Mutant NSCLC
Author(s):
Helena A. Yu, MD, examines the patient selection criteria for potentially using osimertinib monotherapy, osimertinib plus chemotherapy, or amivantamab combined with lazertinib in the first-line treatment of advanced EGFR-mutant non-small cell lung cancer.
- How will you potentially select patients in frontline EGFR mutant advanced NSCLC for:
- Osimertinib monotherapy
- Osimertinib + chemotherapy
- Amivantamab + Lazertinib
Related Videos
Related Content
